特别制药公司ALK报告说,2024年创下845万美元收入记录,预计2025年增长9-13%。 Specialty pharma company ALK reports record $845M revenue in 2024, forecasts 9-13% growth in 2025.

一家专业制药公司ALK报告说,2024年销售增长15%,收入达到8.45亿美元,这是有史以来最好的一年。 ALK, a specialty pharmaceutical company, reported a 15% sales growth in 2024, reaching US$845 million in revenue, its best year ever. 之所以取得这一成功,主要是因为平板产品销售额增长了24%,而且欧洲表现良好。 This success was largely due to a 24% increase in tablet sales and strong performance in Europe. ALK的EBIT比值上升到20%,自由现金流增至7.9亿丹麦克朗。 ALK's EBIT margin rose to 20%, with free cash flow increasing to DKK 790 million. 2025年,该公司预计收入将进一步增长9-13%,并打算扩展到诸如厌食和食品过敏等新领域。 For 2025, the company expects a further 9-13% revenue growth and aims to expand into new areas like anaphylaxis and food allergies.